within Pharmacolibrary.Drugs.ATC.V;

model V09IX09
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0001,
    adminDuration  = 600,
    adminMass      = 185 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00025,
    k12             = 3.0,
    k21             = 3.0
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>V09IX09</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Gallium (68Ga) edotreotide is a radiolabeled somatostatin analog used as a diagnostic imaging agent in positron emission tomography (PET) for the localization of somatostatin receptor-positive neuroendocrine tumors. It is not a therapeutic drug, but a diagnostic agent. The agent is currently in clinical use for neuroendocrine tumor imaging.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adult human subjects based on typical PET radiotracer characteristics and published data on closely related radiolabeled somatostatin analogues; no direct PK studies for (68Ga) edotreotide are available.</p><h4>References</h4><ol><li><p>Shastry, M, et al., &amp; Bomanji, JB (2010). Distribution pattern of 68Ga-DOTATATE in disease-free patients. <i>Nuclear medicine communications</i> 31(12) 1025–1032. DOI:<a href=\"https://doi.org/10.1097/MNM.0b013e32833f635e\">10.1097/MNM.0b013e32833f635e</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20926978/\">https://pubmed.ncbi.nlm.nih.gov/20926978</a></p></li><li><p>Hartmann, H, et al., &amp; Brogsitter, C (2014). Dosimetric measurements of (68)Ga-high affinity DOTATATE: twins in spirit - part III. <i>Nuklearmedizin. Nuclear medicine</i> 53(5) 211–216. DOI:<a href=\"https://doi.org/10.3413/Nukmed-0667-14-05\">10.3413/Nukmed-0667-14-05</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25029274/\">https://pubmed.ncbi.nlm.nih.gov/25029274</a></p></li><li><p>Zhu, W, et al., &amp; Huo, L (2020). Head-to-Head Comparison of . <i>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</i> 61(6) 897–903. DOI:<a href=\"https://doi.org/10.2967/jnumed.119.235093\">10.2967/jnumed.119.235093</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31676731/\">https://pubmed.ncbi.nlm.nih.gov/31676731</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end V09IX09;
